“As India works towards strengthening its healthcare ecosystem, the upcoming Budget is an opportunity to reinforce the fundamentals of pharmaceutical manufacturing. Greater focus on quality linked incentives, support for domestic API production, and continued investment in compliance driven infrastructure will help Indian pharma companies scale responsibly. For mid sized manufacturers, ease of doing business, faster regulatory clearances, and targeted tax rationalisation can unlock capacity expansion without compromising on standards. A predictable policy environment will be critical for ensuring that Indian medicines remain trusted, accessible, and globally competitive," said Arpit Bhatia, Director, Laborate Pharmaceuticals.